Gilead Sciences Statistics
Total Valuation
Gilead Sciences has a market cap or net worth of CAD 299.23 billion. The enterprise value is 325.16 billion.
| Market Cap | 299.23B |
| Enterprise Value | 325.16B |
Important Dates
The last earnings date was Thursday, October 29, 2026.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Dec 15, 2026 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -1.59% |
| Shares Change (QoQ) | +0.64% |
| Owned by Insiders (%) | 0.09% |
| Owned by Institutions (%) | 90.20% |
| Float | 1.24B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 20.28 |
| PS Ratio | 6.75 |
| PB Ratio | 16.05 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.19 |
| P/OCF Ratio | 14.45 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.29, with an EV/FCF ratio of 16.51.
| EV / Earnings | n/a |
| EV / Sales | 7.31 |
| EV / EBITDA | 15.29 |
| EV / EBIT | 19.13 |
| EV / FCF | 16.51 |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 2.02.
| Current Ratio | 1.38 |
| Quick Ratio | 1.08 |
| Debt / Equity | 2.02 |
| Debt / EBITDA | 1.77 |
| Debt / FCF | 1.90 |
| Interest Coverage | 11.72 |
Financial Efficiency
Return on equity (ROE) is -22.45% and return on invested capital (ROIC) is 36.82%.
| Return on Equity (ROE) | -22.45% |
| Return on Assets (ROA) | 13.47% |
| Return on Invested Capital (ROIC) | 36.82% |
| Return on Capital Employed (ROCE) | 30.06% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 2.59M |
| Profits Per Employee | -322,511 |
| Employee Count | 17,000 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 3.38 |
Taxes
In the past 12 months, Gilead Sciences has paid 1.89 billion in taxes.
| Income Tax | 1.89B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +32.24% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +32.24% |
| 50-Day Moving Average | 31.31 |
| 200-Day Moving Average | 28.71 |
| Relative Strength Index (RSI) | 60.58 |
| Average Volume (20 Days) | 7,130 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.55 |
Income Statement
In the last 12 months, Gilead Sciences had revenue of CAD 43.99 billion and -5.48 billion in losses. Loss per share was -0.63.
| Revenue | 43.99B |
| Gross Profit | 35.17B |
| Operating Income | 16.82B |
| Pretax Income | -3.59B |
| Net Income | -5.48B |
| EBITDA | 20.81B |
| EBIT | 16.82B |
| Loss Per Share | -0.63 |
Balance Sheet
The company has 11.29 billion in cash and 37.24 billion in debt, with a net cash position of -25.95 billion.
| Cash & Cash Equivalents | 11.29B |
| Total Debt | 37.24B |
| Net Cash | -25.95B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 18.39B |
| Book Value Per Share | 2.10 |
| Working Capital | 6.46B |
Cash Flow
In the last 12 months, operating cash flow was 20.56 billion and capital expenditures -992.34 million, giving a free cash flow of 19.56 billion.
| Operating Cash Flow | 20.56B |
| Capital Expenditures | -992.34M |
| Depreciation & Amortization | 4.02B |
| Net Borrowing | 1.82B |
| Free Cash Flow | 19.56B |
| FCF Per Share | n/a |
Margins
Gross margin is 79.95%, with operating and profit margins of 38.23% and -12.46%.
| Gross Margin | 79.95% |
| Operating Margin | 38.23% |
| Pretax Margin | -8.17% |
| Profit Margin | -12.46% |
| EBITDA Margin | 47.31% |
| EBIT Margin | 38.23% |
| FCF Margin | 44.22% |
Dividends & Yields
This stock pays an annual dividend of 0.67, which amounts to a dividend yield of 1.97%.
| Dividend Per Share | 0.67 |
| Dividend Yield | 1.97% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 1.59% |
| Shareholder Yield | 3.57% |
| Earnings Yield | -1.84% |
| FCF Yield | 6.58% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Gilead Sciences has an Altman Z-Score of 4.14 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.14 |
| Piotroski F-Score | 5 |